Ke WM - Search Results

1

Consecutive evaluation of immunoglobulin M and G antibodies against hepatitis E virus.

Ke WM, Tan D, Li JG, Izumi S, Shinji Y, Hotta H, Yao JL. Ke WM, et al. J Gastroenterol. 1996 Dec;31(6):818-22. doi: 10.1007/BF02358608. J Gastroenterol. 1996. PMID: 9027645

2

[Relationship between fatal severe from hepatitis occurred during chronic hepatitis B and superinfections of hepatotropic B e system status].

Ke WM, Lin GL, Ye YL, Lai J, Li JG. Ke WM, et al. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005 Mar;19(1):52-4. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2005. PMID: 16201474 Chinese.

3

Etiological investigation of fatal liver failure during the course of chronic hepatitis B in southeast China.

Ke WM, Li XJ, Yu LN, Lai J, Li XH, Gao ZL, Chen PJ. Ke WM, et al. J Gastroenterol. 2006 Apr;41(4):347-51. doi: 10.1007/s00535-005-1781-y. J Gastroenterol. 2006. PMID: 16741614

4

Influence of chronic HBV infection on superimposed acute hepatitis E.

Cheng SH, Mai L, Zhu FQ, Pan XF, Sun HX, Cao H, Shu X, Ke WM, Li G, Xu QH. Cheng SH, et al. Among authors: ke wm. World J Gastroenterol. 2013 Sep 21;19(35):5904-9. doi: 10.3748/wjg.v19.i35.5904. World J Gastroenterol. 2013. PMID: 24124337 Free PMC article.

5

Evaluation of changes of serum hepatitis B surface antigen from a different perspective.

Wu ZQ, Tan L, Liu T, Gao ZL, Ke WM. Wu ZQ, et al. Among authors: ke wm. World J Gastroenterol. 2015 Mar 7;21(9):2739-45. doi: 10.3748/wjg.v21.i9.2739. World J Gastroenterol. 2015. PMID: 25759544 Free PMC article.

6

Discriminant function for prognostic indexes and probability of death in chronic severe hepatitis B.

Ke WM, Ye YN, Huang S. Ke WM, et al. J Gastroenterol. 2003;38(9):861-4. doi: 10.1007/s00535-003-1162-3. J Gastroenterol. 2003. PMID: 14564632

7

Portalsystemic hemodynamic changes in chronic severe hepatitis B: An ultrasonographic study.

Su ZZ, Shan H, Ke WM, He BJ, Zheng RQ. Su ZZ, et al. Among authors: ke wm. World J Gastroenterol. 2008 Feb 7;14(5):795-9. doi: 10.3748/wjg.14.795. World J Gastroenterol. 2008. PMID: 18205274 Free PMC article.

8

What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?

Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM. Yan Y, et al. Among authors: ke wm. World J Gastroenterol. 2012 Sep 7;18(33):4604-9. doi: 10.3748/wjg.v18.i33.4604. World J Gastroenterol. 2012. PMID: 22969236 Free PMC article.

9

Pretreatment HBsAg level and an early decrease in MELD score predict prognosis to lamivudine treatment for HBeAg-negative acute-on-chronic liver failure.

Lai J, Lin CS, Yang L, Chen SR, Zhang YQ, Ke WM. Lai J, et al. Among authors: ke wm. Clin Res Hepatol Gastroenterol. 2014 Jun;38(3):331-6. doi: 10.1016/j.clinre.2013.10.012. Epub 2013 Dec 30. Clin Res Hepatol Gastroenterol. 2014. PMID: 24388342

10

Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure.

Lai J, Yan Y, Mai L, Zheng YB, Gan WQ, Ke WM. Lai J, et al. Among authors: ke wm. Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):154-9. doi: 10.1016/s1499-3872(13)60025-9. Hepatobiliary Pancreat Dis Int. 2013. PMID: 23558069

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters